Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
Compounded products are not FDA-approved, and the FDA has not evaluated them for safety, efficacy, or quality
Plus, they offer the possibility of combining elements from different medications for a potentially more effective approach
Its primary role is helping your cells produce energy and repair damage
You cannot reliably distinguish between them by color alone
